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Summary
Excessive secretion of glucagon is amajor contributor to the development of diabetic hyperglycemia. Secretion of glucagon
is regulated by various nutrients, with glucose being a primary determinant of the rate of a cell glucagon secretion. The intra-
islet action of insulin is essential to exert the effect of glucose on the a cells since, in the absence of insulin, glucose is not
able to suppress glucagon release in vivo. However, the precisemechanismbywhich insulin suppresses glucagon secretion
from a cells is unknown. In this study, we show that insulin induces activation of GABAA receptors in the a cells by receptor
translocation via an Akt kinase-dependent pathway. This leads tomembrane hyperpolarization in the a cells and, ultimately,
suppression of glucagon secretion. We propose that defects in this pathway(s) contribute to diabetic hyperglycemia.Introduction
Glucose stimulates insulin secretion from islet b cells but sup-
presses glucagon secretion from the a cells. A fine balance
between insulin and glucagon secretion maintains the blood glu-
cose levels within a narrow physiological range. However, the
way these hormones are regulated within the pancreas is largely
unknown.
Studies on islet microvasculature have shown that the a cells
lie downstream from the b cells. Before insulin enters the circu-
lation, its local intra-islet concentration is relatively high (Bonner-
Weir and Orci, 1982). Insulin inhibits glucagon release within
islets (Maruyama et al., 1984), likely via its action directly on
the a cells (Kaneko et al., 1999; Kisanuki et al., 1995). In drug-
induced insulin deficiency in dogs, glucose failed to suppress
glucagon secretion in the absence of exogenous insulin (Green-
baum et al., 1991; Starke et al., 1987). These results support the
concept that intra-islet insulin action is essential for suppression
of glucagon in response to hyperglycemia (Muller et al., 1971).
In patients with type 2 diabetes, an oral glucose load induced
a paradoxical rise in glucagon secretion, which could be normal-
ized with optimal administration of insulin, suggesting that the
dysfunctional regulation of pancreatic a cells in diabetes is re-
lated to insulin deficiency and an anomalous internal environ-
ment of the islets (Greenbaum et al., 1991; Hamaguchi et al.,
1991). However, this defect is undefined because of an inade-
quate understanding of the mechanisms underlying suppres-
sion of glucagon by insulin in response to hyperglycemia.
Secretion of glucagon from a cells is regulated by various fac-
tors, including glucose, zinc, and the chemical transmitter
g-aminobutyric acid (GABA) (Pipeleers et al., 1985; IshiharaCELL METABOLISM 3, 47–58, JANUARY 2006 ª2006 ELSEVIER INC.et al., 2003). The role of GABA and the A type GABA receptor
(GABAAR) in the regulation of glucagon release has been dem-
onstrated (Braun et al., 2004; Rorsman et al., 1989). GABA is
a major inhibitory neurotransmitter in the mammalian central
nervous system (CNS) and is synthesized from glutamic acid
by glutamic acid decarboxylase (GAD) (Gerber, 1980). Activa-
tion of GABAAR, a Cl
2 ion channel, results in membrane hyper-
polarization as a consequence of an inward Cl2 flux (Kittler and
Moss, 2003). In the CNS, GABAARs are subject to modulation by
their subunit composition, localization, number and phosphory-
lation states, and variance of GABA concentration in the synap-
tic cleft (Chebib and Johnston, 1999; Mody and Pearce, 2004).
Pancreatic b cells contain high concentrations of GABA and
GAD (Taniguchi et al., 1979). GABA is localized in ‘‘synaptic’’-
like microvesicles within b cells that are distinct from the insulin-
containing large dense core vesicles, suggesting that exocyto-
sis of pancreatic GABA is similar to the process found in neurons
(Reetz et al., 1991; Sorenson et al., 1991). Functional GABAARs
are expressed in the a cells (Hales and Tyndale, 1994; Rorsman
et al., 1989).
It has been proposed that, during hyperglycemia, GABA is
co-released with insulin from the b cells and acts on GABAARs
on the a cells to reduce their secretion of glucagon (Rorsman
et al., 1989). However, this hypothesis has been contested be-
cause of a lack of evidence for a parallel enhancement of
GABA release with insulin in response to glucose stimulation
(Rorsman et al., 1989). The failure to detect an increase in
GABA release does not exclude the possibility that there is an
increase in the responsiveness of GABAARs on a cells upon
hyperglycemia; however a clear-cut mechanism has not been
delineated.DOI 10.1016/j.cmet.2005.11.015 47
A R T I C L EFigure 1. Expression of GABAAR subunits in cell lines and islets
A) a (a-TC6) and b (MIN6) cell line and islet (human and rat) mRNA were used in one-step RT-PCR reactions using subunit-specific primers. Brain mRNA was used as
a positive control while reactions devoid of mRNA were used as a negative control (Brain (B) g3, Ba2).
B) Expression of b subunits within islet a cells. Representative confocal micrographs of pancreatic sections of mouse or rat pancreas (not shown) dual-stained for glucagon
(green) and the GABAAR (b2/3 subunit, in red). The panels (B1) below represent high magnification of inset from (B).
C) Expression of the GABAAR b2/3 subunit (red) in mouse pancreatic b cells (stained in green with anti-insulin).
D) The a1 subunit appears to be ubiquitously colocalized with both glucagon (a cells, D) and insulin (b cells, D1).
E) Representative confocal micrographs of dispersed single rat islet cell stained for glucagon (green) and costained for the GABAAR b2/3 (red) subunit (n = 5, at least 100
cells were examined for each experiment).While searching for an endogenous modulator regulating
GABAAR activity in pancreatic islets, we found that in cultured
neurons and cells expressing functional GABAARs, insulin can
enhance GABAAR activity via translocation of the receptors
from an intracellular pool to the cell surface (Wang et al.,
2003). In particular, Akt, a serine/threonine kinase, was identi-
fied as the key phosphorylating enzyme involved in conveying
insulin signal to the GABAARs (Wang et al., 2003). We now pro-
pose a mechanism whereby hyperglycemia-induced suppres-
sion of glucagon secretion from the a cells is through membrane
translocation of GABAARs via insulin action directly on the a
cells. In this model, insulin rapidly activates Akt kinase, leading
to phosphorylation and translocation of GABAAR to the cell sur-
face, thereby enhancing the responsiveness to GABA released
from the b cells. Activation of the GABAARs results in membrane
hyperpolarization and suppression of glucagon secretion. We
further propose that the excessive secretion of glucagon in dia-
betic subjects is a consequence of the ‘‘insulin resistance’’ that48occurs in the a cells. As a result, the inhibitory effect of glucose
on glucagon secretion is impaired because of defects in the
insulin-Akt-GABAAR-glucagon secretion pathway.
Results
Expression of GABAA receptor subunits in the a cells
The major subunit combination for a functional heteropenta-
meric GABAAR in the CNS has an abg configuration (Mody
and Pearce, 2004). Using RT-PCR, we detected transcripts of
a (mainly a1), b(1-3), and g (mainly g3) GABAAR subunits in both
isolated rat and human pancreatic islet cells (Figure 1A). Similar
results were obtained from glucagon-secreting mouse a-TC6
(Figure 1A) and IN-R1-G9 cells (data not shown). Variations in
expression of individual GABAAR subunits were noticed in a-
TC6 cells with significant expression of g2 rather than g3 sub-
units and expression of lower levels of the b1 subunit (Figure 1A).CELL METABOLISM : JANUARY 2006
GABAAR and glucagon secretionNorthern blot analysis (not shown) further confirmed the expres-
sion of GABAAR subunit isoform transcripts a (mainly a1), b (b1-3),
and g (mainly g3) in both isolated rat islets and a cell lines. The
subunit expression and presumptive GABAAR configuration is
in good agreement with previous reports (Rorsman et al., 1989;
Wendt et al., 2004).
Immunostaining in paraffin-embedded mouse pancreatic
sections revealed that GABAAR b2/3 subunits were localized pri-
marily within the glucagon-positive a cells (Figure 1B), while little
was localized within the insulin-containing b cells (Figure 1C).
Pronounced expression of GABAAR in the a cells was also ob-
served in rat pancreatic sections (data not shown). The staining
pattern for the a1 GABAAR subunit was more diffuse and not as
specific to one particular cell type within the pancreatic islets
(Figure 1D). Indeed, RT-PCR (Figure 1A) and Northern blot (not
shown) results showed that the a1 isoform (but not a2 or a3) is ex-
pressed within the rat and human islets, as well as the clonal cell
lines (Figure 1A). Dispersed single-rat islet cells stained for glu-
cagon and GABAAR b2/3 subunits demonstrated that the
GABAARs were localized to the plasma membrane in addition
to an intracellular reserve (Figure 1E). These findings indicate
that pancreatic a cells express different GABAAR subunits, likely
in a pattern whereby the a1 subunit combines with b1/2/3 and g3
subunits.
Insulin-induced GABAA receptor activation in a cells
To study the action of insulin on glucagon suppression in a cells,
two well-characterized a cell lines were used, glucagon-secret-
ing IN-R1-G9 (Drucker et al., 1991) and a-TC6 cells (Yamada
et al., 2001).
Immunostaining revealed a rapid translocation of Akt from the
cytosol to the cell surface upon insulin stimulation in IN-R1-G9
cells (Figure 2A). Akt activation by insulin was congruent with
translocation of the GABAAR to the plasma membrane (Fig-
ure 2B). A staining profile characteristic of membrane receptor
clusters was observed in insulin-treated a cells (see arrows, Fig-
ure 2B), suggesting increased expression of functional recep-
tors at the cell surface in response to insulin stimulation. These
results were further confirmed in a-TC6 cells (Figure 2C). Double
labeling for the intracellular reserve pool (green) and plasma
membrane-localized GABAARs (red) showed an increase in
the GABAARs at the cell surface following insulin treatment,
with reductions in intracellular reserves (Figure 2C), indicating
that insulin stimulates GABAAR membrane translocation in
a cells.
The role for Akt in mediating insulin action on GABAAR trans-
location was investigated using quantitative Cell-ELISA. In both
a-TC6 and IN-R1-G9 cells, insulin stimulation resulted in a dra-
matic increase in the density of GABAARs at the cell surface
(Figure 2D, p < 0.01). Notably, wortmannin (WM), an inhibitor
of PI3-kinase, the Akt upstream molecule, diminished insulin-
induced GABAAR translocation (Figure 2D). In contrast, inhibi-
tors of PKA or PKC had no significant effect on insulin-induced
GABAAR translocation (Figure 2D), excluding the involvement of
these kinases in insulin-induced GABAAR translocation. These
data indicate that insulin-stimulated GABAAR translocation oc-
curs via a PI3-kinase/Akt-dependent pathway.
Insulin-induced GABAAR membrane translocation was also
evident in rat islet a cells. Dual staining for GABAAR and gluca-
gon or insulin demonstrated that GABAARs were predominantlyCELL METABOLISM : JANUARY 2006localized in the glucagon-containing cells (Figure 2E, ‘‘Ctrl’’)
and very little in insulin-positive cells (Figure S1 available with
this article online). Remarkably, the insulin-treated islet cells
exhibited increased GABAARs at the cell surface of the gluca-
gon-containing cells (Figure 2E); this was blocked by WM pre-
treatment (Figure 2E) although WM, by itself, had no effect on
the basal GABAARs cellular distribution in the glucagon-
positive islet cells (p > 0.05). The insulin-induced GABAARs
translocation is further illustrated in a representative line profile
of fluorescent intensities across the glucagon-positive islet cells
(Figure 2F, upper). Quantitative analysis of the ratio of mem-
brane/cytosol (Figure 2F, middle) or membrane/total GABAAR
(Figure 2F, lower) from at least 100 cells further indicated that
insulin treatment resulted in significant receptor membrane re-
cruitment (p < 0.001), which was significantly inhibited by WM
(#p < 0.05).
We have previously demonstrated, in neurons and HEK293
cells expressing GABAAR, that Akt phosphorylates the b2 sub-
unit at serine 410 (S410) within the major intracellular loop be-
tween TM3 and TM4 domains containing the RXRRRXS motif,
a putative consensus Akt phosphorylation site (Wang et al.,
2003). We thus determined if the RXRRRXS motif of the b1, b2,
and b3 subunits identified in a cells (Figure 2G) is also necessary
for the GABAAR translocation. In vitro phosphorylation assays
using glutathione S-transferase (GST) fusion proteins of the ma-
jor intracellular loops of the b1, b2, or b3 subunits of GABAAR
showed that Akt kinase phosphorylated GST-b1, GST-b2, and
GST-b3, but not GST alone, or GST-a or g fusion proteins (Fig-
ure 2H). Notably, single-site mutants GST-b1(S409A), GST-
b2(S410A), GST-b3(S409A) (but not GST-b3(S408A)) completely abol-
ished the Akt-mediated phosphorylation. For further validation,
GABAAR translocation was determined in IN-R1-G9 cells tran-




FLAG), and g3 subunits and stained for GABAARs
at the cell surface using anti-FLAG antibody. As shown (Fig-
ure 2I), insulin increased the numbers of GABAARs at the cell
surface in IN-R1-G9 cells transiently expressing a1b1g3,
a1b2g3, or a1b3g3 subunits of GABAAR; this was dramatically re-
duced in the cells expressing a1(b1(S409A))g3, a1(b2(S410A))g3,
a1(b3(S409A))g3, or a1(b3(S408AS409A))g3 but not in the cells express-
ing a1b3(S408A)g3. These findings suggest that insulin-stimulated
translocation of the GABAARs to the cell surface on a cells oc-
curs via phosphorylation of serine residues in the Akt consensus
sites of the b subunit receptor.
We next determined the effect of insulin on GABA-induced
transmembrane current (IGABA) using the perforated patch-
clamp technique. In a-TC6 cells, the GABA-evoked current
was concentration dependent and sensitive to the GABAAR an-
tagonist, bicuculline (BIC); the peak amplitude of IGABA in individ-
ual cells varied from 8 to 150 pA. Application of insulin enhanced
IGABA by w21% (p < 0.01, n = 5). This was prevented by WM
treatment (Figures 3A and 3B, p < 0.05, n = 5), while the drug
had no effects on IGABA under basal conditions (not shown).
The effect of insulin on IGABA was also studied in isolated rat
a cells. The IGABA was stable under control conditions and aver-
aged 10.6 6 1.6 pA; addition of insulin increased IGABA by 22%
(Figures 3C and 3D, 16 0.0 versus 1.226 0.05, p < 0.05, n = 3).
This effect was reversed by addition of WM (1.226 0.05 versus
1.02 6 0.10, n = 2). A similar effect of insulin and WM on IGABA
was also observed in cells isolated from guinea pig islets (data
not shown).49
A R T I C L EFigure 2. Insulin-induced GABAAR plasma membrane translocation is Akt kinase dependent
A–B) Serum-starved IN-R1-G9 cells were treated with or without insulin (100 nM, 10 min) and immunostained for endogenous Akt (A) or GABAAR (b2/3 subunits) (B). Arrows
indicate the translocation of Akt (A) and GABAAR (B) to the plasma membrane by insulin.
C) a-TC6 cells were treated as described above and were immunolabeled for the endogenous intracellular reserve pool of GABAARs (green) and for the cell-surface-
expressed receptors (red).
D) The cell-surface endogenous GABAARs in a-TC6 and IN-R1-G9 cells were quantified by Cell-ELISA.
E) Insulin-induced GABAAR membrane translocation is shown in dispersed rat islet cells. Cells with no treatment (Ctrl) or treated with 100 nM insulin (Ins, 10 min) were
stained for glucagon (a, green), and endogenous GABAARs b2/3 subunit (b, red) and confocal images were taken as described in the Experimental procedures. The (c)
panels are merged images of (a) and (b); the (d) panels are Differential Interference Contrast (DIC) images of the same field of views; images in the (e1) and (e2) panels
are the glucagon-positive islet cells as framed in the left panels that are obtained under high magnification (3400). In parallel, some groups of cells were pretreated
with 100 nM wortmannin (WM) for 15 min before being subjected to insulin treatment (WM+Ins). The data shown represent typical results of 3–6 independent experiments
(at least 100 cells were examined for each experimental condition). GABAARs were found to be localized primarily within the glucagon-positive cells (E).
F) Upper: A representative line profile of fluorescence intensities across a single glucagon-positive islet cell along a preset line for the distance increment is shown (Ctrl, no
treatment; Ins, treatment of 100 nM insulin for 10 min; WM, treatment of 100 nM wortmannin; WM+Ins, treatment of 100 nM insulin for 10 min in the presence of WM).
Quantification was made from at least 100 cells and expressed as a ratio of membrane/cytosol (F, middle) or membrane/total GABAAR (F, lower).50 CELL METABOLISM : JANUARY 2006
GABAAR and glucagon secretionFigure 3. Insulin potentiates GABA evoked currents
in a cells
A) Effect of insulin and wortmannin (WM) on GABA-
induced current, IGABA, in a-TC6 cells was deter-
mined using the perforated patch whole-cell config-
uration. GABA (1 mM) evoked currents in a-TC6 cells
under conditions of control (no addition), insulin
treatment (Ins, 100 nM, 8–10 min), pretreatment
with wortmannin (100 nM, 10 min) plus insulin
(Ins+WM), and pretreatment with bicuculline (Bic,
100 mM, 5 min).
B) The bar graph shows the normalized GABA cur-
rents (to ‘‘no addition’’) from five independent experi-
ments (no add. versus Ins = 1 6 0.0 versus 1.21 6
0.05, *p < 0.01; Ins versus Ins+WM = 1.216 0.06 ver-
sus 1.01 6 0.05, #p < 0.05).
C) Current responses were elicited by application of
GABA (1 mM) to rat a cells. Currents were measured
in the perforated-patch configuration before (no ad-
dition) or 5 min after application of insulin (100 nM)
or wortmannin (100 nM, 10 min) plus insulin (Ins+
WM) to the bath.
D)Bar graph shows normalized GABA currents (to no addition) from three independent experiments except the WM data was obtained from two independent experiments.
Data of a-TC6 cells and rat islet a cells were obtained from the same cells and are presented as means6 SEM (no add. versus Ins = 16 0.0 versus 1.226 0.05, *p < 0.05;
Ins versus Ins+WM = 1.226 0.05 versus 1.026 0.10). The significance was examined by one-way ANOVA test and Post Hoc Tukey (for a-TC6 cells) or Student’s t test (for
rat islet a cells).Insulin-induced activation of GABAARs leads
to suppression of glucagon secretion
Based on the outlined hypothesis, we expect that blocking ei-
ther insulin signaling or inactivating GABAARs in a cells should
block suppression of glucagon secretion from the islet a cells.
To verify, a ‘‘paracrine’’ GABA environment was simulated in
a cells by adding 10 nM GABA, a physiologically appropriate
GABA concentration (Winnock et al., 2002). We observed that,
under these conditions, application of insulin suppressed gluca-
gon secretion by w35% in a-TC6 cells (p < 0.001, Figure 4A).
Whereas WM completely reversed insulin-suppressed glucagon
secretion, the drug had little effect on basal glucagon secretion
(Figure 4A). Inactivation of the GABAARs by coapplication of BIC
also significantly reversed the insulin action on glucagon secre-
tion (p < 0.05), although BIC had no significant effects on basal
glucagon secretion (p > 0.05, Figure 4A). Similar results were ob-
tained with IN-R1-G9 cells (Figure 4B). These results indicate
that suppression by insulin of glucagon secretion in the a cells
was abolished when the insulin signaling was blocked or
GABAARs were inactivated in the a cells.
To examine the mechanism in a more physiological setting,
we measured glucagon secretion in isolated rat islets where, un-
der high-glucose conditions, GABA release from the b cells is
unchanged (Smismans et al., 1997; Rorsman et al., 1989), while
insulin release is increased and can act on the a cells. As shown,
glucose treatment resulted in a significant reduction of glucagon
secretion (Figure 4C) and was reversed by WM or BIC, althoughCELL METABOLISM : JANUARY 2006the drugs by themselves had no significant effects on the gluca-
gon release (Figure 4C).
Correspondingly, in human islets that express GABAARs pri-
marily in the glucagon-positive a cells (Figure 4D), glucose sig-
nificantly enhanced insulin production (Figure 4F, p < 0.01) and
reduced glucagon secretion (Figure 4E, p < 0.01). WM abolished
the glucose-induced reduction in glucagon release (Figure 4E,
p < 0.05), with no significant effect on glucose-stimulated insu-
lin secretion from the islets (Figure 4F). Moreover, glucose-
suppressed glucagon secretion was also reversed upon inacti-
vation of the GABAARs by BIC (Figure 4E, p < 0.05), although the
drug had no significant effect on glucose-stimulated insulin se-
cretion (Figure 4F). At low glucose (2 mM), glucagon secretion
was not affected by WM or BIC (Figure 4E), but insulin secretion
tended to increase (Figure 4F, p > 0.05). Although preliminary,
these results support the notion that the suppressive effect of
glucose on glucagon secretion is mediated by the action of insu-
lin on the a cells via PI3-kinase/Akt-dependent modulation of
GABAAR activity.
To rule out extraneous pharmaceutical effects on intracellular
protein kinases or channel activities in the a cells and to further
confirm that insulin’s action on glucagon secretion is mediated
by Akt kinase and GABAARs, we developed complementary ex-
periments directly targeting Akt or the b subunit(s) of GABAAR.
Viral transduction using adenoviral vector constructs encoding
wild-type (Ad-wt), dominant-negative (Ad-DN), or constitutively
active (Ad-CA) Akt (Katome et al., 2003) resulted in a dose-G)A schematic representation of membrane topology of GABAAR b subunits and an alignment of the conserved putative Akt kinase target sequence in the intracellular loop
between transmembrane domains 3 and 4 (targeted serine residue is highlighted in red).
H) GST-fusion proteins containing the intracellular loop between transmembrane domains 3 and 4 of a1, a3, g3, b1, b1(S410A), b3, b3(S408A), b3(S409A), b3 (S408A/S409A), b2,
b2(S410A), along with GST alone as a control, were subjected to in vitro phosphorylation assays using recombinant active Akt1 (see Experimental procedures). The assay
mixtures were subjected to SDS-PAGE and visualized by autoradiography (top). Coomassie blue staining of the same SDS gel shows that similar amounts of GST fusion
proteins were used in each reaction (bottom).




subunits (DNA ratio = 2:2:1) or plasmids of GABAAR subunits with the same combinations but the b subunits were replaced by various mutants (b1(S409A), b2(S410A), b3(S408A),
b3(S409A), or b3(S408A/S409A)). Transfected cells were serum deprived, stimulated with insulin (100 nM, 10 min), and stained for the cell surface GABAARs using anti-FLAG
antibody under nonpermeant condition.51
A R T I C L EFigure 4. Insulin-suppressed glucagon secretion from a cells is wortmannin and/or bicuculline sensitive
Glucagon secretion from a-TC 6 cells (A), In-R1-G9 cells (B), isolated rat islets (C), and human islets (E) was measured in KRB using RIAs. Briefly, Serum-deprived cells (A
and B) were incubated with 100 nM insulin alone (Ins), 100 nM insulin plus 100 nM WM (Ins+WM), or 100 nM insulin plus 10 mM BIC (Ins+Bic) or incubated with WM or BIC
alone during the glucagon secretion assays (n = 6–12). GABA (10 nM) was used during the incubation period to mimic the paracrine environment (see Figure 7 and Exper-
imental procedures). Glucagon secretion from rat (C) and human (E) islets was assayed as described above for (A) and (B) except that GABA was omitted and glucose was
used instead of insulin (n = 13 [rat], n = 4 [human]). The ‘‘n’’ corresponds to the number of separate independent experiments performed with rats; with the human assays,
‘‘n’’ corresponds to the number of experiments that were performed repeatedly using islets from the same donor. Images (D) were obtained by confocal microscopy using
dispersed human islet cells coimmunostained for GABAAR (b2/3, green) and glucagon (red). Insulin secretion (F) from isolated human islets under experimental conditions as
described in (E) was measured using RIA. *p < 0.05, **p < 0.01, ***p < 0.001.dependent increase in the expression of the three types of Akt,
while transduction of vector itself (Ad-green fluorescent protein
[GFP]) had no noticeable effect on endogenous Akt expression
(Figure 5A). Insulin-stimulated Akt phosphorylation (pS473) in
the transduced cells was viral concentration dependent
(Figure 5B). An Akt kinase assay (Figure 5C) showed that insulin
increased Akt kinase activity in the nontransduced cells (w15-
fold, p < 0.001) and the GFP-expressing cells (w14-fold, p <
0.001). Akt kinase activity under basal conditions was relatively
high in cells expressing Ad-wt-Akt (w10-fold over basal, p <
0.01); insulin treatment further enhanced Akt activity by w5-
fold (p < 0.01). However, insulin had no further stimulatory ef-
fects on Akt activation in cells expressing Ad-CA-Akt, as the ki-
nase activity was significantly elevated under basal conditions
(w40-fold, p < 0.005) (Figure 5C). In contrast, in the cells ex-
pressing Ad-DN-Akt, while basal activity was not significantly al-
tered, insulin-stimulated Akt activation was completely abol-
ished (Figure 5C).
The transduction procedures had no effect on the glucagon
secretion, as measured in parallel in virally transduced a cells52(Figure 5D). In the presence of basal levels of GABA (10 nM), in-
sulin suppressed glucagon secretion in cells expressing Ad-
GFP by w34% (p < 0.001) and in cells expressing Ad-wt-Akt
by w29% (p < 0.005). On the contrary, this suppressive effect
was completely abolished in cells expressing Ad-DN-Akt (p <
0.05). In the absence of insulin, glucagon secretion was mod-
estly but significantly suppressed in cells expressing Ad-wt-
Akt (w15%, p < 0.05); further suppression was seen in cells ex-
pressing Ad-CA-Akt (w34%, p < 0.001). These findings indicate
that ablating Akt kinase activity diminishes insulin-induced sup-
pression of glucagon secretion. Moreover, as elevation of Akt
kinase activity mimics insulin effects, activation of Akt kinase
appears to be sufficient to suppress glucagon secretion in
a cells.
Insulin-suppressed glucagon secretion is diminished
in a cellular model of insulin resistance
We further investigated insulin-directed GABAAR membrane
trafficking and glucagon secretion in a cellular model of insulin
resistance. This model was established by incubating In-R1-G9CELL METABOLISM : JANUARY 2006
GABAAR and glucagon secretionFigure 5. Insulin-suppressed glucagon release is mediated by the Akt-GABAAR pathway
In-R1-G9 cells were transduced with various GFP-tagged adenovirus carrying Akts (GFP, green fluorescent protein; wt, wild-type Akt; CA, constitutively active Akt; DN,
dominant-negative Akt). Serum-deprived cells were treated with (‘‘+’’) or without (‘‘2’’) insulin (100 nM, 5 min), and total Akt protein content (A) or Akt phosphorylation (B)
was determined by Western blotting using anti-Akt or anti-phospho-Akt antibodies. A transduction rate >99% of IN-R1-G9 cells was obtained at a viral concentration
ofw1 3 108 pfu/ml as determined by GFP fluorescence.
C) Serum-deprived In-R1-G9 cells transduced with various viral constructs, or nontransduced control cells (Ctrl) were incubated with vehicle (blank bars) or insulin (100 nM,
5 min; black bars). Following the treatment, total Akt was immunopurified and kinase activity was determined using the specific Akt substrate Crosstide (see Experimental
procedures).
D) Under similar transduction conditions, glucagon was measured in IN-R1-G9 cells transduced with various Ad-Akts using RIAs.a cells in culture medium containing high concentrations of
glucose (25 mM) and insulin (100 nM) (high Glu/Ins) for 24 hr
(as previously described for muscle; [Huang et al., 2002], adipo-
cytes [Lu et al., 2001], or liver cells [Nakajima et al., 2000]). We
found that acute insulin stimulation stimulated tyrosine phos-
phorylation of the insulin receptor (IR) in the control cells (p <
0.001); this was significantly diminished after 24 hr of high Glu/
Ins pretreatment (Figure 6A, p < 0.01). As expected, insulin dra-
matically stimulated Akt activation in the control cells as exam-
ined by Akt phosphorylation (w12-fold, Figure 6B, p < 0.001)
and kinase assays (w14-fold, Figure 6C, p < 0.001). This was
significantly reduced after a 24 hr preincubation with high Glu/
Ins (Figure 6C, p < 0.01), although chronic high Glu/Ins had no
significant effect on protein levels of IR (Figure 6A, p > 0.05) or
Akt (Figure 6B, p > 0.05). These results suggest that, despite
an elevation in basal Akt activity (w3-fold, Figures 6B and 6C,
p < 0.01), a significant reduction of signal transduction following
acute insulin stimulation occurred in these a cells after chronic
high Glu/Ins treatment.
Under identical experimental conditions, we assayed gluca-
gon secretion and found a significant suppression of glucagon
secretion by insulin in the control cells (33%, p < 0.01). However,
while the basal glucagon secretion was markedly decreased
(Figure 6D, p < 0.05), acute insulin treatment did not further sup-
press glucagon release in cells chronically exposed to high Glu/
Ins (Figure 6D, p > 0.05). These data suggested that insulin was
not able to suppress glucagon secretion when insulin signaling
was blunted. Of note, chronic treatment with Glu/Ins resultedCELL METABOLISM : JANUARY 2006in a relatively small, yet significant, elevation in Akt kinase activ-
ity (Figure 6C, p < 0.01; Glu/Ins versus Ctrl = w3-fold versus
w14-fold). This ‘‘basal’’ elevation of Akt activity (Figure 6C) thus
appeared to have a significant suppressive effect on glucagon
secretion (Figure 6D, p < 0.05).
To determine whether this ‘‘basal’’ elevation of Akt activity is
sufficient to cause translocation of GABAARs and hence the
subsequent suppression of glucagon release, we examined the
distribution of GABAARs in the a cells following chronic treat-
ment with high Glu/Ins. Cell-surface GABAAR staining and quan-
tification revealed that, in control In-R1-G9 cells, insulin signifi-
cantly increased GABAAR membrane translocation (Figure 6E,
upper-left, p < 0.01). However, acute insulin treatment did not
significantly increase GABAAR membrane translocation in cells
pretreated with high Glu/Ins (Figure 6E, upper-right, p > 0.05)
likely due to a significant basal elevation of the number of
GABAAR at the cell surface (Figure 6E, p < 0.01). These observa-
tions indicate that increased GABAAR translocation associated
with decreased glucagon production after chronic high Glu/Ins
treatment is mostly due to the elevation of the basal Akt kinase
activity. Therefore, GABAAR translocation, in response to tran-
sient increases in insulin, is a prerequisite in modulating gluca-
gon secretion.
Discussion
Excessive glucagon secretion from pancreatic a cells is a major
contributor to the development of diabetic hyperglycemia.53
A R T I C L EFigure 6. Exposure of IN-R1-G9 cells to high glucose and insulin reduces insulin signaling associated with diminished insulin suppression on glucagon secretion
A–B) IN-R1-G9 cells were incubated for 24 hr in control or high Glu/Ins medium (glucose 25 mM, insulin 100 nM). Total cell lysates (w50 mg) were subjected to Western
blotting for (A) IR, phospho-IR, (B) Akt and phospho-Akt.
C) Total Akt proteins were immunopurified and the Akt kinase activity was determined.
D) Glucagon from the medium was assayed using RIA with control IN-R1-G9 cells or IN-R1-G9 cells treated with high Glu/Ins. Results are the means6 SEM of 5–6 experi-
ments (*p < 0.05, **p < 0.01, ***p < 0.001).
E) Translocation of GABAARs in the control (left two panels) or the high-Glu/Ins-treated IN-R1-G9 cells (right two panels) was determined by cell-surface staining of en-
dogenous GABAAR (b2/3). The representative images show that insulin-induced GABAAR translocation occurs in the control cells (left, top panel) but not in the cells treated
with high Glu/Ins. The middle row shows the Differential Interference Contrast (DIC) images of the same cells shown in the top panels; bottom row shows the merged im-
ages of DIC and fluorescent. (F) The bar graph shows the quantitative results of the cell-surface staining (means 6 SEM of 100 to 300 cells analyzed).Understanding the physiological mechanisms controlling gluca-
gon secretion and the causes of hyperglucagonemia is therefore
vital to understanding diabetes.
In this report, we demonstrate that glucose-induced suppres-
sion of glucagon release occurs by means of insulin-induced
membrane translocation/activation of the GABAARs in a cells
(Figure 7). Our results indicate that the insulin-induced GABAAR
translocation/activation is Akt kinase dependent but not depen-
dent on other kinases such as PKA or PKC. This is supported, at
least in part, by evidence from previous studies. First, although
both b1, and b3 subunits have been previously shown to be
phosphorylated by both PKA and PKC, PKC-induced phosphor-
ylation leads to a reduction of GABAAR function (Brandon et al.,
2000; McDonald and Moss, 1997). Second, PKC-induced phos-
phorylation of the neuronal b3 subunit occurred on both S408
and S409 (Brandon et al., 2000). In contrast, Akt-mediated
phosphorylation of the b3 subunit occurs only on S409. Third,
modulation of GABAAR by PKC occurred mainly via changing
channel gating or conductance rather than altering GABAAR
trafficking (Brandon et al., 2000). Finally, the PKA signaling
is likely to be distinct from the signaling pathway(s) following54IR activation, as IN-R1-G9 cells used in these studies have
been found to be PKA deficient (Drucker et al., 1991). Therefore,
insulin-induced GABAAR membrane translocation/activation
in the a cells appears to be solely dependent on Akt kinase
activity.
Our data are in line with previous findings that blocking
GABAARs attenuated GABA-induced suppression of glucagon
secretion in guinea pig islets (Rorsman et al., 1989) or rat islets
(Wendt et al., 2004). Rodent a cells have been shown to possess
a low resting membrane conductance (0.1–0.4 nS) (Barg et al.,
2000; Bokvist et al., 1999). Under these conditions, a current
a few pA in amplitude can substantially affect the membrane
potential. It is therefore conceivable that a 22% increase of
the GABAAR-mediated current leads to a significant hyperpolar-
ization of the cell and reduction of electrical activity. Our data
further show that inactivating Akt kinase by using either pharma-
cological agents or adenoviral-delivered dominant-negative
constructs dramatically abolished insulin-suppressed glucagon
secretion, indicating that insulin-induced suppression of gluca-
gon release requires Akt activity. Moreover, bypassing IR activa-
tion by elevating Akt kinase activity by adenoviral delivery ofCELL METABOLISM : JANUARY 2006
GABAAR and glucagon secretionFigure 7. A model showing the Akt-GABAAR path-
way in mediating glucose-induced suppression of
glucagon release in a cells
When glucose levels increase, insulin released from
b cells activates the IR present on a cells. Activation
of Akt leads to phosphorylation of b subunits of
GABAAR that causes rapid translocation of the re-
ceptor to the plasma membrane. As GABA is con-
stantly released from b cells (Rorsman et al., 1989),
increased GABAAR numbers at the cell surface in-
creases the efficacy of the receptor-mediated inhib-
itory currents (Cl2) and membrane hyperpolarization
occurs. In turn, membrane hyperpolarization shuts
down voltage-dependent Ca2+ channels (Go¨pel
et al., 2004) and as a result inhibits a cell exocytosis
and glucagon release. The Ca2+-dependent exocy-
tosis machinery is not shown.CA-Akt significantly suppressed glucagon secretion, suggest-
ing that activation of Akt kinase is sufficient to suppress gluca-
gon release. In our present study, the Akt vectors encode Akt1
(Katome et al., 2003) and the antibody used in the Akt kinase as-
says recognizes only Akt1. We thus believe that Akt1 may be
the predominant isoform that mediates insulin action on the
a cells.
Interestingly, an earlier study (Gilon et al., 1991) showed that,
in the presence of arginine, glucose-induced inhibition of gluca-
gon release was not altered by bicuculline. The reasons for this
discrepancy are unclear and further study is required. Nonethe-
less, although we believe that the receptor translocation is a ma-
jor mechanism leading to an increase in GABAAR number at the
a cell surface upon insulin stimulation, we cannot rule out the
possibility that insulin stimulation might increase the stability
of the GABAARs on the cell surface (Luscher and Keller, 2004)
or lead to a reduction in endocytosis (Cinar and Barnes, 2001).
Further experiments are required to clarify the mechanism.
Previous insulin infusion studies in diabetic animal models
(Greenbaum et al., 1991; Starke et al., 1987) and diabetic pa-
tients (Hamaguchi et al., 1991) demonstrated that, while glucose
alone could not suppress glucagon secretion, insulin sup-
pressed glucagon release in the diabetic subjects. These in
vivo studies indicated a crucial role for intra-islet insulin in per-
mitting glucose to suppress glucagon secretion (Greenbaum
et al., 1991; Starke et al., 1987). Our current findings provide
new insights into the mechanisms underlying insulin-induced
suppression of glucagon secretion at the cellular and molecular
level.
In the a cells, while chronic treatment with high Glu/Ins signif-
icantly elevated basal Akt activity that was associated with in-
creased GABAAR numbers at the cell surface and suppressed
glucagon secretion, the subsequent addition of insulin did not
further increase GABAAR numbers at the cell surface or further
suppress glucagon secretion. Though these results indicate
that elevation of Akt activity with consequent GABAAR mem-
brane translocation is sufficient to suppress glucagon secretion
in the a cells, they do not fully explain the situation in diabeticCELL METABOLISM : JANUARY 2006subjects, i.e., diabetic hyperglucagonemia. Presumably these
findings reflect the compensatory mechanism(s) of the islet cells
(e.g., enhanced insulin secretion and reduced glucagon secre-
tion to compensate for peripheral insulin resistance) in the early
stage of insulin resistance (Bergman et al., 2002; Ferrannini,
1998). Yet, it is conceivable that when insulin resistance be-
comes severe, b cells may lose their capacity to compensate
and diabetic hyperglucagonemia might develop as a result of at-
tenuated insulin action on the a cells. Further experiments using
diabetic animal models are required to address this possibility.
An impaired counter-regulatory response to hypoglycemia is
a critical problem for diabetic patients receiving exogenous in-
sulin treatment (Cryer, 1994). Studies in humans demonstrated
that intra-islet hyperinsulinemia is the major contributor that pre-
vents the glucagon response to hypoglycemia (Banarer et al.,
2002). The importance of insulin in modulating the a cell secre-
tion has been highlighted recently by the ‘‘switch-off’’ hypothe-
sis that the proper responsiveness of a cells to hypoglycemia
requires ‘‘turning off’’ insulin action on the a cells (Hope et al.,
2004; Zhou et al., 2004). The question raised by our present
results is whether the artificially high levels of insulin given to
diabetic patients might chronically upregulate GABAAR in the
a cells, turning off the ability to secrete glucagon in insulin-
induced hypoglycemia. This is a testable hypothesis and will be
explored in the future.
Although activation of the insulin-Akt-GABAAR pathway under
high-glucose conditions appears to be a prominent mechanism
underlying glucose-suppressed glucagon secretion in a cells,
this pathway may not be the sole mechanism regulating gluca-
gon secretion. For example, glucose and insulin may also di-
rectly exert effects on glucagon secretion from glucagon-
secreting a cells (Ronner et al., 1993; Ravier and Rutter, 2005).
In contrast, studies by Franklin et al. (2005) demonstrated that
in isolated rat a cells, while insulin inhibited glucagon secretion,
glucose (16 mM) stimulated glucagon secretion from the rat
a cells pretreated with low glucose. The discrepancy is likely
due to the use of different assay systems and assay conditions.
Furthermore, the modulation of glucagon release may involve55
A R T I C L Eother islet hormones including somatostatin (Cejvan et al., 2003;
Hayashi et al., 2003), neurotransmitters such as L-glutamate
(Hayashi et al., 2003), or zinc ions (Ishihara et al., 2003). Never-
theless, these studies do not exclude the possibility that the
GABA-GABA receptor system might be involved in this modula-
tion (Hayashi et al., 2003; Chessler et al., 2002; Gammelsaeter
et al., 2004). These mechanisms appear to constitute precise
regulatory networks that operate to regulate glucagon release
and hence to maintain blood glucose within a narrow physiolog-
ical range.
While changing the total number of GABAARs on the cell sur-
face significantly modulates GABAAR function (Wang et al.,
2003), altering GABAAR gating or conductance is also important
(Mody and Pearce, 2004). It is interesting to note that PKC, a cru-
cial component mediating nutrition-induced insulin resistance in
muscle (Kim et al., 2004), fat (Muller et al., 1991), and liver (Lam
et al., 2002), is activated and translocated from the cytosol to
the plasma membrane following sustained high-fat and/or high-
glucose treatment (Lam et al., 2002; Nakajima et al., 2000).
Translocation of PKC isoforms to the plasma membrane may al-
low the direct interaction of PKC and GABAAR (Brandon et al.,
2002). It has been shown previously that direct binding of
GABAAR with activated PKC reduces the amplitude of GABA-
activated currents (Connolly et al., 1999; Krishek et al., 1994).
It is thus of great interest to investigate the membrane trafficking
and the gating of GABAAR in coupling glucagon secretion under
diabetic conditions.
Experimental procedures
Cell culture and islet isolation
In-R1-G9 and a-TC6 cells were cultured as described (Drucker et al., 1991;
Yamada et al., 2001). Islets were isolated from male Sprague-Dawley rats
(200–250 g) and female guinea pigs (200–250 g) by collagenase digestion
(Chan et al., 1993). Single islet cells were prepared by dispersion of freshly
isolated islets in Ca2+-free buffer. Human islets were obtained from the Hu-
man Islet Laboratory, University of Pennsylvania. The islets or the dispersed
islet cells were maintained in RPMI-1640 tissue culture medium for 2–30 hr
prior to the experiments.
Plasmid construction and transfection
The cDNA of the intracellular loop region between transmembrane domains
3 and 4 of GABAAR subunits a3, b1, b2, b3, and g3 were cloned into pGEX-
4T-1 for bacterial expression of GST-fusion proteins. Full-length cDNAs for
GABAAR subunits b1, b2, and b3 were cloned into pCMV-Tag 4B for mam-
malian expression (see Supplemental data). Site-directed mutagenesis
was used to introduce S409A in GABAAR-b1, S410A in GABAAR-b2, and
S408A/S409A in GABAARb3 in pGEX-4T and pCMV-Tag 4B, using the Quick-
change mutagenesis kit (Stratagene, La Jolla, California). Mammalian cell
transfections were carried out using Lipofectamine 2000plus (Invitrogen).
RT-PCR
One hundred nanograms of RNA template was used to analyze the expres-
sion of different GABAAR subunits using One-step RT-PCR kit (Qiagen,
Valencia, CA) in a final volume of 25 ml (see Supplemental data for primer
sequences).
Adenoviral transduction
Adenoviral (Ad) expression vectors tagged with green fluorescent protein
(GFP) (Ad-GFP) and carrying wild-type Akt (Ad-wt-Akt), constitutively active
(CA) Ad-CA-Akt, or dominant-negative (DN) Akt (Ad-DN-Akt) have been de-
scribed (Katome et al., 2003). Purified virus was added tow85% confluent
In-R1-G9 or a-TC6 cells for 2 hr. Cells were washed and incubated for
16 hr in fresh medium. Transduction rate was determined by examining the
cells for GFP under a fluorescence microscope. With 108 pfu/ml, a transduc-
tion rate of >99% was routinely achieved.56Western blotting and assays of Akt kinase activity
Western blot analysis was performed as described (Wang et al., 2003). The
primary antibodies used were anti-IR IgG (1:500), anti-phospho-tyrosine
IgG (1:1,000) (Upstate, Lake Placid, New York), anti-Akt IgG (1:1,000), or
anti-phospho-Akt (Ser473) (1:500, Cell Signaling Tech, Beverley, Massachu-
setts). Immunoprecipitation of Akt and the kinase assay were performed us-
ing Crosstide (Upstate) as a specific Akt substrate (Wang et al., 1998).
Phosphorylation assay of GST fusion proteins
Generation of GST-GABAAR fusion plasmids are described in Supplemental
data. In vitro phosphorylation assays were performed as reported (Wang
et al., 2003) using recombinant Akt1 kinase (Cell Signaling Technology,
Massachusetts).
Confocal imaging and Cell-ELISA assay
For imaging studies, IN-R1-G9, and a-TC6 cells were grown on poly-D-lysine
(Sigma)-coated glass coverslips, while for islets, dispersed rat islet cells were
prepared as reported previously (El Kholy et al., 2003). Serum-starved cells
were stimulated with insulin (100 nM, 10 min) or vehicle and fixed using
3.7% formaldehyde. After fixation, cells were permeablized with 0.1% Triton
X-100, except cells used for translocation studies. Antibodies used were
guinea pig anti-insulin, rabbit anti-glucagon, mouse anti-somatostatin (all
from Dako, 1:1000), Cy3-, Cy5-, and FITC-conjugated secondary antibodies
(Jackson Labs, 1:1000), rabbit anti-GABAAR a1 subunit (UBI 1:1000), mouse
anti-GABAAR b2/3 subunit (UBI 1:200), and rabbit anti-phospho-Akt (Ser473,
1:500). Cell-ELISAs were performed as described to quantify the transloca-
tion of GABAARs (Wang et al., 2003). Mouse anti-FLAG (Sigma, 1:800) anti-
body was used in the cells transfected with various FLAG-tagged GABAAR
vectors as shown in Figure 2C. The dual immunostaining was used to distin-
guish cell-surface and intracellular GABAARs. Briefly, for cell-surface label-
ing, fixed cells were incubated, under nonpermeant conditions, with mono-
clonal antibody against an extracellular epitope of the GABAAR b2/3 subunit
(UBI 1:200) and subsequently with Cy3-conjugated anti-mouse IgG (Jackson
Labs, 1:1000). Following this, the intracellular receptors were stained, after
cell permeabilization, with rabbit anti-GABAAR a1 subunit (UBI 1:1000) and
FITC-conjugated anti-rabbit IgG (Jackson Labs, 1:1000). All multiple stain-
ings were performed sequentially, and individual image channels were
scanned separately using a Ziess Laser Scanning Microscope (Model 510).
Quantification of surface staining used Metamorph analysis software (Uni-
versal Imaging Corp) based on total pixel intensity per unit area. Image
thresholds were equal for all experimental conditions, and the background
was subtracted from the total number of pixels in the threshold. Total num-
bers of pixels were then calculated per individual cell. Typically, 100–300
cells were analyzed.
GABAAR membrane translocation in islet cells was measured using the line
profile function of ImagePro Plus 5.0 software (Media Cybernetics Inc., Silver
Spring, Maryland) based on fluorescence intensities across single cells along
a preset line for each distance increment. Quantification was made from at
least 100 cells and expressed as a ratio of membrane/cytosol or mem-
brane/total GABAAR.
Glucagon and insulin secretion assays
For glucagon secretion assays, the a cells grown in 24-well plates (70%–80%
confluency) were washed twice and preincubated with 20 mM glucose in
KRB (in mM: 115 NaCl, 5 KCl, 24 NaHCO3, 2.5 CaCl2, 1 MgCl2, 10 HEPES,
and 0.2% bovine serum albumin) for 30 min at 37ºC. Cells were subsequently
treated with either low (2 mM) or high (20 mM) glucose in 500 ml KRB contain-
ing test substances as indicated. GABA (10 nM) was included in the assay
buffer during the incubation period. Islets secretion (10 islets in a 5 ml assay
tube) was performed in the KRB buffer except that GABA was omitted and
glucose was used in place of insulin. Glucagon and insulin levels were mea-
sured by radioimmunoassay (RIA) kits (Linco Research, St. Louis, Missouri).
Pilot studies were performed for the time-dependent secretions. Glucagon
and insulin were detected within 5 min with a plateau of 15 min with propor-
tional rate of change up to 2–4 hr (data not shown).
Electrophysiology
Patch-clamp experiments were performed in the perforated whole-cell con-
figuration using an EPC-9 amplifier and Pulse software (HEKA, Lambrecht,
Germany). For a-TC6 cells, drugs were applied with computer-controlledCELL METABOLISM : JANUARY 2006
GABAAR and glucagon secretionmulti-barreled micro-perfusion system (SF-77B, Warner Instruments, Ham-
den, Connecticut). Intracellular solutions (in mM) contained 130 KCl,
10 NaCl, 0.5 MgCl2, 1 EGTA, 5 HEPES, and 0.15 mg/ml Nystatin (pH 7.3).
The standard bath solution (in mM) contained 138 NaCl, 5.6 KCl,
1.2 MgCl2, 2.6 CaCl2, 5.6 glucose, 5 HEPES (pH 7.4). For rat a cells, GABA
(1 mM) was applied using an oocyte injection system (Nanoliter 2000, World
Precision Instruments, Sarasota, Florida). Identification of a cells was based
on size and Na+-current inactivation (Go¨pel et al., 2004). The extracellular so-
lution (in mM) consisted of 118 NaCl, 20 TEACl, 5.6 KCl, 2.6 CaCl2, 1.2 MgCl2,
10 HEPES, and 5 glucose (pH 7.4). The pipette solution (in mM) contained
50 Cs2SO4, 60 CsCl, 10 KCl, 1 MgCl2, 10 HEPES and 0.24 mg/ml amphoter-
icin B (pH 7.3). The current responses were recorded at a holding potential of
270 mV. Insulin was added to the bath solution when the responses to two
consecutive GABA applications (1 min interval) were stable. For the statistical
analysis, the peak current responses were measured.
Statistical analysis
All data are presented as mean 6 SEM. Statistical analysis was done by
a Student’s t test or ANOVA tests as appropriate. Significance was assumed
at a p value of less than 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001).
Supplemental data
Supplemental data include one figure and supplemental experimental proce-
dures and can be found with this article online at http://www.cellmetabolism.
org/cgi/content/full/3/1/47/DC1/.
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